Bavarian Nordic's MVA-BN Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
Bavarian Nordic A/S has announced that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security — Burkholderia pseudomallei and Burkholderia mallei.
“The award of this contract illustrates the strength of our MVA-BN vaccine platform technology, which has been developed through a decade-long partnership with the US Department of Health and Human Services,” said Anders Hedegaard, President and CEO of Bavarian Nordic. “As part of our strategy to expand our biodefense business beyond smallpox, we are pleased to add DTRA to our list of government partners with whom we work to develop novel biodefense vaccines.”
DTRA is the fourth US Government agency to collaborate with Bavarian Nordic on the development of novel biodefense vaccines. Other ongoing collaborations include the development of vaccines against smallpox, filoviruses (Ebola and Marburg) and foot-and-mouth disease, for which the company has received funding from the Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the Department of Homeland Security’s Science and Technology Directorate.
Under this new USD 0.5 million contract Bavarian Nordic will design, generate and test MVA-BN-based recombinant vaccines against Burkholderia. If the contract yields a successful proof of concept, DTRA may support further development of the vaccine through a larger contract award.
Related News
-
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance